Acellera Therapeutics Unveils AceForce 1.0: A Novel Family of Next-Generation Neural Network Potential Accelerating Drug Discovery
Investors Contact:
Gianni De Fabritiis (CEO)
investors@acellera.com
(Meet us during JPM in San Francisco)
Business Information Contact:
F. Chevalier (Head of Business Development)
f.chevalier@acellera.com
Acellera Therapeutics, a pioneer in computational chemistry and AI-driven drug discovery, today announced the launch of AceForce 1.0, its groundbreaking neural network potential (NNP) model designed to deliver quantum-level accuracy for predicting atomic interactions—an essential factor in identifying promising drug candidates earlier and more efficiently.
“AceForce 1.0 marks a major leap forward by bringing quantum-like accuracy into everyday drug discovery workflows,” said Gianni De Fabritiis, Founder and Chief Executive Officer of Acellera Therapeutics. “Even in this initial release, AceForce 1.0 matches or surpasses state-of-the-art molecular potentials developed over decades. As we expand our training sets, speed up calculations, and refine these AI-driven models, we look forward to empowering scientists to identify promising molecules more quickly, reliably, and affordably.”
Key Highlights of AceForce 1.0
- Quantum-Level Accuracy: Built on a proprietary training set of many millions of quantum mechanical (QM) calculations, AceForce 1.0 closely mirrors high-level QM methods to provide reliable potential energy surfaces.
- Broad Applicability: AceForce 1.0 supports a wide range of chemical elements and charged molecules, enabling its use across vast areas of drug discovery and chemical space.
- Optimized Efficiency: AceForce 1.0 can run its simulations at roughly twice the speed of previous-generation NNPs.
- Validated via QuantumBind-RBFE: Acellera Therapeutics employed its QuantumBind-RBFE platform to benchmark AceForce 1.0 against publicly available “gold standard” datasets for relative binding free energy (RBFE). See paper.
Availability and Future Plans
- AceForce 1.0 is immediately available at HuggingFace for non-profit use and demo purposes.
- Tutorials for calculations for small molecules and protein-small molecule complexes.
- Future iterations of AceForce aim to push accuracy boundaries even further, solidifying this family of NNPs as a cornerstone in next-generation drug discovery.
For information, including licensing options and guidance on integrating this advanced NNP into your drug discovery programs, please visit Acellera’s blog post or contact info@acellera.com.
About Acellera Therapeutics
At Acellera Therapeutics, we believe in transforming drug discovery from a slow, artisanal process into a computable, scalable, and efficient endeavor. Guided by our mission to engineer medicines through AI-driven innovation, we relentlessly pursue new methods and technologies to accelerate the design of tomorrow’s drugs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106031067/en/
